Mutation screening of ASMT, the last enzyme of the melatonin pathway, in a large sample of patients with intellectual disability. - Inserm - Institut national de la santé et de la recherche médicale Accéder directement au contenu
Article Dans Une Revue BMC Medical Genetics Année : 2011

Mutation screening of ASMT, the last enzyme of the melatonin pathway, in a large sample of patients with intellectual disability.

Cecile Pagan
  • Fonction : Auteur
  • PersonId : 906046
Anne Dumaine
  • Fonction : Auteur
  • PersonId : 906049
Sarah Moreno
  • Fonction : Auteur
  • PersonId : 906050
Arjan de Brouwer
  • Fonction : Auteur
  • PersonId : 899154
Hilde van Esch
  • Fonction : Auteur
  • PersonId : 906051
Didier Lacombe
  • Fonction : Auteur
  • PersonId : 886371
Sylvain Briault
  • Fonction : Auteur
  • PersonId : 863252
Marjolein Willemsen
  • Fonction : Auteur
  • PersonId : 906056

Résumé

BACKGROUND: Intellectual disability (ID) is frequently associated with sleep disorders. Treatment with melatonin demonstrated efficacy, suggesting that, at least in a subgroup of patients, the endogenous melatonin level may not be sufficient to adequately set the sleep-wake cycles. Mutations in ASMT gene, coding the last enzyme of the melatonin pathway have been reported as a risk factor for autism spectrum disorders (ASD), which are often comorbid with ID. Thus the aim of the study was to ascertain the genetic variability of ASMT in a large cohort of patients with ID and controls. METHODS: Here, we sequenced all exons of ASMT in a sample of 361 patients with ID and 440 controls. We then measured the ASMT activity in B lymphoblastoid cell lines (BLCL) of patients with ID carrying an ASMT variant and compared it to controls. RESULTS: We could identify eleven variations modifying the protein sequence of ASMT (ID only: N13H, N17K, V171M, E288D; controls only: E61Q, D210G, K219R, P243L, C273S, R291Q; ID and controls: L298F) and two deleterious splice site mutations (IVS5+2T>C and IVS7+1G>T) only observed in patients with ID. We then ascertained ASMT activity in B lymphoblastoid cell lines from patients carrying the mutations and showed significantly lower enzyme activity in patients carrying mutations compared to controls (p = 0.004). CONCLUSIONS: We could identify patients with deleterious ASMT mutations as well as decreased ASMT activity. However, this study does not support ASMT as a causative gene for ID since we observed no significant enrichment in the frequency of ASMT variants in ID compared to controls. Nevertheless, given the impact of sleep difficulties in patients with ID, melatonin supplementation might be of great benefit for a subgroup of patients with low melatonin synthesis.
Fichier principal
Vignette du fichier
1471-2350-12-17.pdf (146.96 Ko) Télécharger le fichier
1471-2350-12-17.xml (51.15 Ko) Télécharger le fichier
Origine : Fichiers éditeurs autorisés sur une archive ouverte
Format : Autre
Loading...

Dates et versions

inserm-00610655 , version 1 (22-07-2011)

Identifiants

Citer

Cecile Pagan, Hany Goubran Botros, Karine Poirier, Anne Dumaine, Stéphane Jamain, et al.. Mutation screening of ASMT, the last enzyme of the melatonin pathway, in a large sample of patients with intellectual disability.. BMC Medical Genetics, 2011, 12 (1), pp.17. ⟨10.1186/1471-2350-12-17⟩. ⟨inserm-00610655⟩
688 Consultations
746 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More